Author + information
- Magda Heras, MD⁎ ()
- ↵⁎Department of Cardiology, Hospital Clinic, IDIBAPS, University of Barcelona Villarroel, 170, 08036 Barcelona, Spain
Basra et al. (1) wrote a timely state-of-the-art paper on “safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease” in the Journal.
As the authors stated, this is a relevant topic because of the aging population we are treating and the associate decrease in renal function they present. On the other hand, potent antithrombotic treatment is the cornerstone therapy in acute coronary syndrome. Therefore, it is mandatory to have a thorough knowledge of how to safely use antiplatelet and anticoagulant agents in patients with renal failure, and thus, this paper is important for clinical practice.
However, there is a misconception in the last paragraph just before “Conclusions.” The authors described dabigatran as being a direct Xa inhibitor; however, dabigatran is an oral direct IIa inhibitor. Besides, dabigatran is not included in Tables 2 and 3 of their report (1), which is a disappointment because dabigatran is already being used in clinical practice and its appearance in the tables would have been of interest.
- American College of Cardiology Foundation